These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 11642202)

  • 21. Are oral contraceptives associated with increased renin-angiotensin activity and risk of nephropathy in diabetic women?
    Wolf G
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):78-9. PubMed ID: 16932398
    [No Abstract]   [Full Text] [Related]  

  • 22. Diabetic nephropathy: implications for renal and cardiovascular outcomes.
    Folan LA; Tuttle KR
    Minerva Med; 2004 Oct; 95(5):385-94. PubMed ID: 15467514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Renin-Angiotensin system and vascular disease in diabetes.
    Deinum J; Chaturvedi N
    Semin Vasc Med; 2002 May; 2(2):149-56. PubMed ID: 16222606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent advances in diabetic nephropathy.
    Marshall SM
    Postgrad Med J; 2004 Nov; 80(949):624-33. PubMed ID: 15537844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].
    Shamkhlova MSh; Trubitsyna NP; Katsaia GV; Goncharov NP; Malysheva NM; Il'in AV; Nikankina LV; Koshel' LV; Shestakova MV
    Ter Arkh; 2008; 80(1):49-52. PubMed ID: 18326228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring.
    Rossing K
    Dan Med Bull; 2007 May; 54(2):79-98. PubMed ID: 17521525
    [No Abstract]   [Full Text] [Related]  

  • 28. The mechanisms underlying altered vascular resistance of glomerular afferent and efferent arterioles in diabetic nephropathy.
    Arima S; Ito S
    Nephrol Dial Transplant; 2003 Oct; 18(10):1966-9. PubMed ID: 13679465
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology.
    Wolf G
    Eur J Clin Invest; 2004 Dec; 34(12):785-96. PubMed ID: 15606719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors modifying plasma activity in diabetic nephropathy.
    Tripathi K; Agarwal JK; Prakash J; Bajpai HS
    J Assoc Physicians India; 1993 Sep; 41(9):616. PubMed ID: 8307932
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of diabetic nephropathy, particularly focusing on drug therapy].
    Gohda T
    Nihon Rinsho; 2016 Apr; 74 Suppl 2():202-6. PubMed ID: 27266088
    [No Abstract]   [Full Text] [Related]  

  • 34. [Diabetic nephropathy--risk factors and incidences].
    Fujita T; Ohi H
    Nihon Rinsho; 1997 Oct; 55 Suppl():789-94. PubMed ID: 9392198
    [No Abstract]   [Full Text] [Related]  

  • 35. Letter: Diabetic nephropathy.
    Wardle EN
    Br Med J; 1975 Aug; 3(5978):306. PubMed ID: 1148792
    [No Abstract]   [Full Text] [Related]  

  • 36. Diabetic nephropathy.
    Demiroğlu H
    QJM; 1997 Jul; 90(7):493. PubMed ID: 9302434
    [No Abstract]   [Full Text] [Related]  

  • 37. Diabetic kidney disease research: where do we stand at the turn of the century?
    Lee HB; Ha H; Kim SI; Ziyadeh FN
    Kidney Int Suppl; 2000 Sep; 77():S1-2. PubMed ID: 10997683
    [No Abstract]   [Full Text] [Related]  

  • 38. Where is dentistry headed?
    Dent Econ; 1972 Oct; 62(10):53-4 passimf. PubMed ID: 4510797
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pathogenic factors in diabetic nephropathy. Where do we come from and where are we headed?].
    Marrón B; Ortiz A; Egido J
    Nefrologia; 2001; 21 Suppl 3():18-23. PubMed ID: 11642202
    [No Abstract]   [Full Text] [Related]  

  • 40. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.